Insider Selling: GeneDx Holdings Corp. (NASDAQ:WGS) CEO Sells 10,559 Shares of Stock

GeneDx Holdings Corp. (NASDAQ:WGSGet Free Report) CEO Katherine Stueland sold 10,559 shares of GeneDx stock in a transaction on Monday, March 17th. The stock was sold at an average price of $96.71, for a total transaction of $1,021,160.89. Following the transaction, the chief executive officer now directly owns 14,865 shares in the company, valued at $1,437,594.15. This represents a 41.53 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Katherine Stueland also recently made the following trade(s):

  • On Thursday, March 13th, Katherine Stueland sold 1,078 shares of GeneDx stock. The shares were sold at an average price of $89.44, for a total transaction of $96,416.32.
  • On Monday, March 10th, Katherine Stueland sold 2,731 shares of GeneDx stock. The stock was sold at an average price of $94.73, for a total transaction of $258,707.63.
  • On Wednesday, January 29th, Katherine Stueland sold 1,657 shares of GeneDx stock. The shares were sold at an average price of $78.48, for a total transaction of $130,041.36.
  • On Tuesday, January 7th, Katherine Stueland sold 51,420 shares of GeneDx stock. The shares were sold at an average price of $94.48, for a total value of $4,858,161.60.
  • On Thursday, January 2nd, Katherine Stueland sold 18,006 shares of GeneDx stock. The stock was sold at an average price of $78.18, for a total transaction of $1,407,709.08.

GeneDx Stock Performance

Shares of WGS stock traded down $4.01 during trading hours on Monday, reaching $94.46. 668,407 shares of the company traded hands, compared to its average volume of 612,654. The firm has a 50-day moving average price of $84.69 and a 200 day moving average price of $70.37. The company has a market cap of $2.65 billion, a P/E ratio of -48.19 and a beta of 1.91. GeneDx Holdings Corp. has a 12-month low of $7.72 and a 12-month high of $115.60. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27.

GeneDx (NASDAQ:WGSGet Free Report) last posted its quarterly earnings results on Tuesday, February 18th. The company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.04 by $0.66. The business had revenue of $95.64 million during the quarter, compared to analyst estimates of $82.24 million. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. As a group, sell-side analysts predict that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. The Goldman Sachs Group lifted their price objective on GeneDx from $70.00 to $80.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 19th. TD Cowen lifted their price target on GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a research report on Tuesday, January 7th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $72.33.

Get Our Latest Analysis on WGS

Institutional Investors Weigh In On GeneDx

A number of institutional investors have recently bought and sold shares of the business. MCF Advisors LLC grew its holdings in GeneDx by 107.7% during the 4th quarter. MCF Advisors LLC now owns 351 shares of the company’s stock valued at $27,000 after buying an additional 182 shares in the last quarter. Sterling Capital Management LLC boosted its position in shares of GeneDx by 877.8% during the fourth quarter. Sterling Capital Management LLC now owns 352 shares of the company’s stock worth $27,000 after acquiring an additional 316 shares during the last quarter. Global Retirement Partners LLC bought a new position in shares of GeneDx during the fourth quarter worth $28,000. Lazard Asset Management LLC purchased a new position in GeneDx during the fourth quarter valued at $35,000. Finally, Comerica Bank bought a new stake in GeneDx in the 4th quarter valued at $50,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

GeneDx Company Profile

(Get Free Report)

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.

See Also

Insider Buying and Selling by Quarter for GeneDx (NASDAQ:WGS)

Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.